CONTACT

Véronique Maguer-Satta, PhD
Group leader
veronique.maguer-satta@lyon.unicancer.fr
+33 478 78 29 07

Cheney D, 4th floor
Centre Léon Bérard
28 rue Laennec
69373 Lyon Cedex 08
France

DEGAUD Michaël
JEANPIERRE Sandrine
Technician Centre Léon Bérard (CLB)
NICOLINI Franck Emmanuel
PH, Hospices Civils de Lyon (HCL)
franck-emmanuel.nicolini@lyon-chu.fr
VOELTZEL Thibault
BEAUMONT Anaïs
DELAY Emmanuel
PH, Clinicien du Centre Léon Bérard (CLB)
emmanuel.delay@lyon.unicancer.fr
ZYLBERSZTEJN Florence
MORAITIS Iris

Master 2

GROCKOWIAK Elodie

Ph.D. student

CLEMENT Flora
GOBERT-GOSSE Stéphanie
BOIRON Sophie
Master 2
CORDIER Kevin
Master 2
GUYOT Boris
Voir les objectifs et projets Voir les publications

Main National Collaborations
Dr B Combourieu, ROVALTAIN, Valence
Dr M Glukhova ; Institut Curie, Paris
Pr O Herault, Dr N Mazure, Dr C Le Bousse-Kerdiles, Dr N. Rochet: Network GRD Niche Tumorale
Pr FX Mahon (Bordeaux),  P Auberger (Nice), Network Phi-LMC
Dr JP Rieu (Physicists, Lyon)
Dr M Le Romancer, CRCL, Lyon
Dr V Petrili, CRCL, Lyon
Dr C Caux, CRCL, Lyon, France. INSERM U1035 (Bordeaux) / Jean-Max PASQUET             

Liste des principales collaborations Internationales
Pr GAO Wei-Qiang, Renji Hospital Stem cell research center, Shanghai, China
Dr ZHU Helen He, Shanghai Jiao Tong University, Shanghai, China
Dr J Erler, Copenhagen, Denmark
Dr K Tanner, Bethesda, USA

National and international networks
GDR ”Micronit”
FI-LMC
Halifax Project

OBJECTIVES

The projects of our lab focus on Bone Morphogenetic Protein (BMP) family members, stem cells, and the tumor niche. We study the effect of the tumor environment on Cancer Stem Cells (CSCs) and their resistance to treatment, using epithelial tumour models and haematopoietic models. Our approach relies on analyzing and modulating the expression of these BMP family members and characterizing their functions. We are developing projects subjecting cancer stem cells to different conditions, which will allow us to evaluate the impact of their interactions with the microenvironment on their ability to resist treatment. We are also studying the functional consequences, in terms of drug response, of interactions between CSCs and cellular or structural components of the tumor niche, by integrating the physical and environmental parameters with, for example, the mechanical constraints.

PROJECT

Previous work

Our work has led to a number of advances in the field of Bone Morphogenic Proteins (BMPs) and stem cells (SCs).  Our work focuses on the hematopoietic system and the mammary gland. We have shown that FLRG regulates hematopoietic stem cells (HSC) by blocking members of the TGFβ family (Activin and certain BMPs), or directly by promoting the regulation of HSCs through adhesion to fibronectin. BMP4 alone regulates the entire megakaryopoiesis, for example mediated by Thrombopoietin (TPO), the effects of which are largely mediated by the autocrine BMP loop. We were further able to demonstrate that chemotherapies alter the relationship between the SC and its microenvironment, the so-called niche. We have shown that in chronic myeloid leukemia (CML), Twist1 is a predictive marker and plays a role in drug resistance. To analyze the epithelial system of the breast, we have developed a simple strategy to isolate human mammary SCs and identified a key role for the enzyme CD10 and β1 integrins in their regulation by their niche, further showing that CD10 is a marker for stem and early progenitor cells that form spheres.

 

Figure Legend.
(A) Mammopshere obtained from primary human mammary epithelial cells isolated from reduction mammoplasty.

(B) Immunofluorescent staining of keratin 14 of a mammosphere.
(C) Hematopoietic stem cell in its niche. (source: Internet Google Image) 
(D) Terminal ductal lobular unit assay. Phase contrast image of 3D structures obtained from mammary stem and progenitor cells grown in matrigel (left) and H&E staining of a cross section of a lobular unit (right).
(E) Erythroid (top) and megakaryocyte (bottom) colonies derived from human hematopoietic stem cells.

 

 

Overview of projects

From a clinical point of view, it is essential to eliminate cancer stem cells responsible for resistance and relapse. Our group and others have demonstrated that BMP molecules, members of the TGFβ superfamily, are key regulators of SCs and their niche in both normal and tumoral contexts. In order to analyze the role of the BMP pathway in the regulation of cancer stem cells (CSCs), we use two models: Chronic Myeloid Leukemia (CML) in a hematopoietic system which constitutes the standard model for the transformation of normal SCs and breast cancer in an epithelial system forming solid tumors, in which the existence of CSCs has been demonstrated but the origin of which remains unknown.

Our preliminary data indicate that, in these two CSC models, there is a deregulation in the BMP pathway. We hypothesized that, as is the case in glioblastoma, an alteration in the BMP signaling pathway and the cellular biological response in the blood and the breast is required to maintain the CSC phenotype and resistance. This could constitute a general mechanism of appearance of CSCs and resistance. We suggested that the deregulation of the BMP pathway could be due to different alterations linked to the various functions of the BMP family and may not necessarily be identical between the different tissues affected. We are testing this hypothesis in our models, using the molecular tools we have developed and are examining the effect of BMP deregulation on CSC appearance and properties such as quiescence, self-renewal, proliferation, differentiation, adhesion, migration, tumorigenic potential, and therapeutic resistance. We are particularly interested in the contribution of the microenvironment towards the maintenance of CSCs (such as the enzymatic function of CD10), resistance and escape from therapies. Lastly, we are currently exploring whether the links between BMP molecules and immune cells may contribute to the escape of CSCs from the immune response. This project is befitting of the wider aim of the lab to explore the role of CD10 and BMPs in the transformation of mammary SCs.

Our medium-term goals are to improve our understanding of the specific mechanisms governing the resistance of SCs and to develop a model system that allows the evaluation of novel targeted therapeutic strategies against SCs in the context of their environment.

PUBLICATIONS

Clement F, Zhu HH, Gao W-Q, Delay E and Maguer-Satta V*. (2015) Update of a Protocol to Quantify Epithelial Early Common Progenitors from Long-Term Primary or Cell Lines Sphere Culture. Curr Protoc Stem Cell Biol. In press

F. E. Nicolini, G. Etienne, V. Dubruille, L. Roy, F. Huguet, L. Legros, S. Giraudier, V. Coiteux, A. Guerci-Bresler,  P. Lenain, P.Cony-Makhoul,  M. Gardembas, E. Hermet, P. Rousselot, S. Amé, M-C. Gagnieu, C. Pivot, S. Hayette,  V. Maguer-Satta, M. Etienne,  S. Dulucq, D. Rea, F-X. Mahon MD. (2015) Nilotinib and pegylated interferon alfa 2a for newly diagnosed chronic phase chronic myeloid leukaemia patients. Results of a multicentric phase II study. Lancet Hematology, 2(1):37-46.

Chapellier C,and Maguer-Satta V. BMP2, a key to uncover luminal breast cancer origin linked to pollutant effects on epithelial stem cells niche. (2015) Molecular & Cellular Oncology. In press.

Casey SC, Vaccari M, Al-Mulla F, Al-Temaimi R, Amedei A, Barcellos-Hoff MH, Brown D, Chapellier M, Christopher J, Curran C, Forte S, Hamid RA, Heneberg P,Koch DC, Krishnakumar PK, Laconi E, Maguer-Satta V, Marongiu F, Memeo L, Mondello C, Raju J, Roman J, Roy R, Ryan E, Ryeom S, Salem HK, Scovassi I, Singh N, Soucek L, Vermeulen L, Whitfield JR, Woodrick J, Colacci A, Bisson WH and Felsher DW (2015) Assessing the Carcinogenic Potential of Environmental Chemicals: The Tumor Microenvironment. Carcinogenesis, Jun;36 Suppl 1:S160-83.

Chapellier C, Bachelard-Cascales E, Schmidt X, Clement F, Treilleux I, Delay E, Jammot A, Menetrier-Caux C, Pochon G, Besançon R, Voeltzel T, Caron de Fromentel, Caux C, Blay JY, Iggo R and Maguer-Satta V. (2015) Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by over-amplifying BMPR1B cell response. Stem Cell Reports, 4(2):239-254.

Maguer-Satta V and Rochet N (2014): La niche des cellules souches : enjeux conceptuels et technologiques pour l’étude des mécanismes normaux et tumoraux (The stem cell niche : conceptual and technical chalenges to understand normal and tumoral mechanisms). Cultures de cellules animales, Chapter, Inserm, 3e édition, Lavoisier. 269-290.

Maguer-Satta V and Laperrousaz B (2014): Ciblage des cellules souches cancéreuses. Metastases, AMGEN Oncologie, John Libbey, Chapter,  volume 9, 71-82.

Laperrousaz B, Jeanpierre S, Sagorny K, Voeltzel T, Ramas S, Kaniewski B, Ffrench M, Salesse S, Nicolini FE, Maguer-Satta V. (2013) Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and BMPRIb overexpression. Blood. 122(23): 3767-3777.

Bachelard-Cascales E, Chapellier M, Delay E and Maguer-Satta V. (2012) A protocol to quantify Mammary Early Common Progenitors from long-term mammosphere culture. Current protocols in Stem Cells Biology. Chapter 1:Unit 1E.7.

Maguer-Satta V, Chapellier M, Delay E and Bachelard-Cascales E. (2011) CD10: a tool to crack the role of stem cells in breast cancer. PNAS. 108: 49.

Maguer-Satta, V. Besançon, R. and Bachelard-Cascales, E. (2011) Neutral endopeptidase (NEP/CD10): a multifaceted environment actor in stem cells, physiological mechanisms and cancer. Stem Cells. 29(3):389-96.

Cosset, E. Hamdan, G. Jeanpierre, S. Voeltzel, T. Sagorny, K. Hayette S. Mahon, F.-X Dumontet, C. Puisieux, A. Nicolini, F. E. and Maguer-Satta V. (2011) Deregulation of TWIST-1 as a novel prognostic factor in chronic myeloid leukemia Blood. 3;117(5):1673-6.

Bachelard-Cascales, E.. Chapellier, M. Delay, E. Pochon, G. Voeltzel, T. Puisieux, A. Caron de Fromentel C and Maguer-Satta. V. (2010) The CD10-enzyme is a key player to identify and regulate Human mammary stem cells. Stem Cells. 28:1081-88

Besançon, R. Valsesia-Wittmann, S. Puisieux, Caron de Fromentel, C and Maguer-Satta, V. (2009) Cancer stem cells: the emerging challenge of drug targeting. Current Medical Chemistry. 16, 394-416

Jeanpierre, S. Nicolini, FE. Kaniewski, B. Dumontet, C. Rimokh, R. Puisieux, A. and Maguer-Satta, V. (2008) BMP-4 mediates TPO effects on megakaryocytic differentiation in human primary cells. Blood.112, 3154-3163

Berger, M. Richard, C. Berger, J. Jeanpierre, S. Nicolini, FE. Tournilhac, O. Michallet, M. and Maguer-Satta, V. (2008). Fludarabine chemotherapy alter cell-to-cell interactions in BM stem cell niche, likely involved in stem cell mobilization failure. Leukemia. 22(11):2131-4

 

CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :